Satte News nachbörslich - Biotech Rakete vor Kurssprung - 500 Beiträge pro Seite

[pharma71]

Knaller News gestern nachbörslich bei der Biotech-Schmiede Gammacan:

Das Unternehmen aus dem Bereich der Krebsforschung hat die Finanzierung für die umfangreiche Testphase des in der Entwicklung befindlichen Produktes endgültig gesichert.

Damit sind die Chancen auf ein marktreifes Produkt das dem Unternehmen und den Anlegern hohe Erträge bringen kann.

Gammacan
Frankfurt: A0B8TX
New York: GCAN


GammaCan Consummates Initial Investment of $500,000 with an Option of up to $2.5 Million Financing Through Sal. Oppenheim jr. & Cie. (Switzerland) Ltd

Tuesday , November 15, 2005 16:00 ET

GIVAT SHMUEL, Israel, Nov 15, 2005 (BUSINESS WIRE) -- GammaCan International (OTC BB: GCAN), a developer of immunotherapies for cancer and other diseases, consummated an initial investment of $500,000.00, by Sal. Oppenheim jr. & Cie. (Switzerland) Ltd., with an option for them to invest an additional $2 million in accordance with a private placement which closed on October 31, 2005. Details of the transaction have been publicly disclosed in a Form 8-K filed with the Securities and Exchange Commission on November 3, 2005.

The use of proceeds will include the continuation of the Company`s Phase II clinical trial of GCAN 101 for the treatment of metastatic cancer. Additionally, the Company is pursuing key strategic alliances and joint ventures to further the product pipeline for which the funds will be utilized.

" We are pleased to have secured these initial funds which will allow us to continue our clinical trial activity and potentially open other sites," stated Vered Caplan, CEO.

" Sal. Oppenheim jr. & Cie. (Switzerland) Ltd, is the Swiss Branch of the largest German Private Bank. Clients of the Bank took down a private placement in the company," stated the Bank representative.

" Sal. Oppenheim jr. & Cie. (Switzerland) Ltd represents a strong partner for Gammacan. Their professionalism and understanding of our goals, we believe, will lead to a long-term relationship that could be very beneficial to the Company as it moves ahead," stated Chaime Orlev, Chief Financial Officer.

About GammaCan:

GammaCan is focusing on the commercialization of a revolutionary anti-cancer immunotherapy that the Company believes will be proven to be effective in reducing the metastatic spread of a wide range of cancers. GammaCan`s proposed treatment is based on IVIG, a safe, relatively non-toxic human plasma-based product, currently used to treat a variety of immune deficiencies and autoimmune diseases. It works by strengthening the patient`s immune system. Many experts currently view immunotherapy as a future alternative to today`s standard chemotherapy. Approximately twenty companies produce IVIG, and annual worldwide sales are currently in excess of 50 metric tones with an estimated value in excess of 1.5 billion USD. IVIG is commonly used to treat certain autoimmune diseases and blood disorders and to replace the antibodies in people who are unable to produce them. For more information about GammaCan visit www.gammacan.com or call the company`s headquarters in Givat Shmuel, Israel at 972 3 5774475.

[Plusquamperfekt]

1. Warum legst du den Thread nicht unter der Aktie ab ?

2. Das gleiche wurde vorhin schon mal geschrieben !